New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, #12, April 1997
State-of-the-Art in the Management of Cancer
Ovarian Cancer-part II
Screening, Diagnosis, Staging, AND Prognosis

Screening

Pelvic Examination

Tumor Markers

  • CA125
  • Complementarity markers
  • Other tumor markers

In vivo Imaging

  • Transabdominal ultrasonography

Histology

Diagnosis

Laparotomy/Laparoscopy

In vitro Diagnostics

  • Biomira
  • Centocor
  • Horus
  • Myriad
  • OncorMed

In vivo Imaging

Staging and Prognosis

Anticancer Drug Development

TOPOISOMERASE I INHIBITORS

Meeting Coverage

Topoisomerase I Inhibitors

From the 21st Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, November 1-5, 1996

Irinotecan

Colorectal Cancer

  • Monotherapy as second-line therapy
  • Combination therapy
  • First-line combination therapy

Lymphoma

Topotecan

Ovarian Cancer

Small Cell Lung Cancer

Metastatic Brain Cancer and High Grade Gliomas

 

New Developments in the Treatment of Gynecologic Cancers

From the 21st Congress of the European Society of Medical Oncology, Vienna, Austria; November 1-5, 1996

 

Invasive Cervical Cancer

Metastatic Cervical Cancer

  • HIV-related invasive cervical cancer

Combination Regimens in Invasive Cervical Cancer

  • Combination of cisplatin and vinorelbine
  • Combination of cisplatin and paclitaxel

Ovarian Cancer

Gemcitabine in Advanced Epithelial Ovarian Cancer

Topotecan

Marimastat for Advanced Ovarian Cancer

Paclitaxel and Ifosfamide in Advanced Ovarian Cancer

Primary Fallopian Tube Carcinoma


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887